Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › mycophenolate mofetil

mycophenolate mofetil

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of mycophenolate mofetil

183 trials tracked of mycophenolate mofetil: 43 in phase 3 or 4 and 11 with published results. The most-cited published study has 535 citations.

183Trials tracked
43Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 17 Phase 3 26 Phase 2 124 Phase 1 7 Other / NA 9
  1. Phase 3 TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) Completed · 535 cited
  2. Phase 3 A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) Completed · 490 cited
  3. Phase 3 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed · 114 cited
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) Completed · 112 cited
  5. Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed · 111 cited
  6. Phase 3 TBI Dose De-escalation for Fanconi Anemia Completed · 109 cited
Show 44 more trials
  1. Phase 4 Belatacept Early Steroid Withdrawal Trial Completed · 33 cited
  2. Phase 3 Methotrexate and Mycophenolate Mofetil for UVEITIS Completed · 18 cited
  3. Phase 3 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients Completed · 13 cited
  4. Phase 3 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Completed · 10 cited
  5. Phase 3 A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) Completed · 5 cited
  6. Phase 4 A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation Completed
  7. Phase 4 Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS Completed
  8. Phase 4 A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients Completed
  9. Phase 4 SCHEDULE Follow Up Visit 5-7 yr Completed
  10. Phase 4 Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients Completed
  11. Phase 4 Improved Induction and Maintenance Immunosuppression in Kidney Transplantation Completed
  12. Phase 4 Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients Completed
  13. Phase 4 Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant Completed
  14. Phase 4 A Study of CellCept (Mycophenolate Mofetil) Combined With Calcineurin Inhibitors in Liver Transplant Patients. Completed
  15. Phase 4 A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients. Completed
  16. Phase 4 Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation Completed
  17. Phase 4 Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients Completed
  18. Phase 4 Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance Completed
  19. Phase 4 Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation Completed
  20. Phase 4 Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients Completed
  21. Phase 4 SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance Completed
  22. Phase 3 A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients Completed
  23. Phase 3 Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch Completed
  24. Phase 3 Belatacept Therapy for the Failing Renal Allograft Completed
  25. Phase 3 Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids Completed
  26. Phase 3 Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) Completed
  27. Phase 3 Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients Completed
  28. Phase 3 A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis Completed
  29. Phase 3 Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens Completed
  30. Phase 3 Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection Completed
  31. Phase 3 First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial Completed
  32. Phase 3 Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed
  33. Phase 3 A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis. Completed
  34. Phase 3 OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients. Completed
  35. Phase 3 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed
  36. Phase 3 A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients. Completed
  37. Phase 3 Study Evaluating Sirolimus in Kidney Transplant Recipients Completed
  38. Phase 2 Stem Cell Transplant for Immunologic or Histiocytic Disorders Completed
  39. Phase 2 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed
  40. Phase 2 Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation Completed
  41. Phase 2 Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients Completed
  42. Phase 2 Treg Modulation With CD28 and IL-6 Receptor Antagonists Completed
  43. Phase 2 Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Completed
  44. Phase 2 Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed

Showing the 50 most-cited and recently-updated of 183 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Mycophenolate mofetil non-inferior to prednisone for first-episode nephrotic syndrome in children
Pediatrics RCT
Mycophenolate mofetil non-inferior to prednisone for first-episode nephrotic syndrome in children Mycophenolate Mofetil Offers Alternative to Steroids for Nephrotic Syndrome
This phase 3 non-inferiority trial randomized 272 children aged 1-10 years with first-episode steroid-sensitive nephrotic syndrome to mycoph…
A new trial shows mycophenolate mofetil works as well as prednisone for children with nephrotic syndrome, with fewer steroid side effects.
May 1, 2026
Switching therapy after rituximab resistance in AQP4-IgG+ NMOSD shows variable relapse outcomes
Oncology Cohort
Switching therapy after rituximab resistance in AQP4-IgG+ NMOSD shows variable relapse outcomes New Hope for Tough-to-Treat Nerve Disorder
This single-center, retrospective case series of 10 adults with AQP4-IgG+ NMOSD who were resistant to rituximab evaluated switching therapy.
Patients with a rare nerve disease who stopped responding to standard treatment found relief after switching to new therapies that prevented…
Frontiers Apr 19, 2026
Nailfold videocapillaroscopy patterns associate with interstitial lung disease and skin fibrosis in systemic sclerosis patients
Rheumatology Cohort
Nailfold videocapillaroscopy patterns associate with interstitial lung disease and skin fibrosis in systemic sclerosis patients Does the tiny pattern in your nailbeds predict serious lung scarring in scleroderma?
This prospective cross-sectional study evaluated 70 patients with systemic sclerosis to assess associations between nailfold videocapillaros…
Tiny changes under fingernails can warn of serious lung scarring in scleroderma patients, linking nail patterns to disease severity and qual…
Frontiers Apr 15, 2026
Individualized insulin strategies may improve glycemic control in pediatric T1DM with exogenous insulin antibody syndrome
Diabetes & Endocrinology Cohort
Individualized insulin strategies may improve glycemic control in pediatric T1DM with exogenous insulin antibody syndrome Can personalized insulin plans help kids with a rare, stubborn form of diabetes?
A retrospective case series of 5 pediatric patients with T1DM complicated by exogenous insulin antibody syndrome found that individualized i…
Doctors helped four of five children with rare diabetes stay in a healthy blood sugar range over 70% of the time using personalized treatmen…
Frontiers Apr 5, 2026
Japanese AAV Cohort Shows MPA Has 67.6% Five-Year Survival; Glucocorticoid Reduction Not Linked to Better Outcomes
Infectious Disease Cohort
Japanese AAV Cohort Shows MPA Has 67.6% Five-Year Survival; Glucocorticoid Reduction Not Linked to Better Outcomes For Japanese patients with a rare autoimmune disease, survival remains challenging
A retrospective cohort study of 460 treatment-naïve Japanese patients with AAV found microscopic polyangiitis (MPA) had the poorest prognosi…
Japanese patients with microscopic polyangiitis face a five-year survival rate of 67.6%, as older age and kidney issues raise death risk.
Frontiers Apr 5, 2026